Abstract:Infection with SARS-CoV-2, the virus that causes COVID-19, can lead to severe lower respiratory illness including pneumonia and acute respiratory distress syndrome, which can result in profound morbidity and mortality. However, many infected individuals are either asymptomatic or have isolated upper respiratory symptoms, which suggests that the upper airways represent the initial site of viral infection, and that some individuals are able to largely constrain viral pathology to the nasal and oropharyngeal tissues. Which cell types in the human nasopharynx are the primary targets of SARS-CoV-2 infection, and how infection influences the cellular organization of the respiratory epithelium remains incompletely understood. Here, we present nasopharyngeal samples from a cohort of 35 individuals with COVID-19, representing a wide spectrum of disease states from ambulatory to critically ill, as well as 23 healthy and intubated patients without COVID-19. Using standard nasopharyngeal swabs, we collected viable cells and performed single-cell RNA-sequencing (scRNA-seq), simultaneously profiling both host and viral RNA. We find that following infection with SARS-CoV-2, the upper respiratory epithelium undergoes massive reorganization: secretory cells diversify and expand, and mature epithelial cells are preferentially lost. Further, we observe evidence for deuterosomal cell and immature ciliated cell expansion, potentially representing active repopulation of lost ciliated cells through coupled secretory cell differentiation. Epithelial cells from participants with mild/moderate COVID-19 show extensive induction of genes associated with anti-viral and type I interferon responses. In contrast, cells from participants with severe lower respiratory symptoms appear globally muted in their anti-viral capacity, despite substantially higher local inflammatory myeloid populations and equivalent nasal viral loads. This suggests an essential role for intrinsic, local epithelial immunity in curbing and constraining viral-induced pathology. Using a custom computational pipeline, we characterized cell-associated SARS-CoV-2 RNA and identified rare cells with RNA intermediates strongly suggestive of active replication. Both within and across individuals, we find remarkable diversity and heterogeneity among SARS-CoV-2 RNA+ host cells, including developing/immature and interferon-responsive ciliated cells, KRT13+ "hillock"-like cells, and unique subsets of secretory, goblet, and squamous cells. Finally, SARS-CoV-2 RNA+ cells, as compared to uninfected bystanders, are enriched for genes involved in susceptibility (e.g., CTSL, TMPRSS2) or response (e.g., MX1, IFITM3, EIF2AK2) to infection. Together, this work defines both protective and detrimental host responses to SARS-CoV-2, determines the direct viral targets of infection, and suggests that failed anti-viral epithelial immunity in the nasal mucosa may underlie the progression to severe COVID-19.

Transient anti-interferon autoantibodies in the airways are associated with efficient recovery from COVID-19

Transient anti-interferon autoantibodies in the airways are associated with recovery from COVID-19

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia

Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019

COVID-19 neutralizing antibodies predict disease severity and survival

The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity

Interferon-α2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities

Nasopharyngeal inflammatory lymphocytes perturbation in COVID-19 severity prediction

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity

SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection

SARS-CoV-2 infection results in immune responses in the respiratory tract and peripheral blood that suggest mechanisms of disease severity

Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19

Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19

More rapid blood interferon α2 decline in fatal versus surviving COVID-19 patients

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison